Evaluation of bone marrow toxic reaction in patients treated with allopurinol Academic Article Article uri icon

Overview

MeSH Major

  • Melanoma
  • Proto-Oncogene Proteins B-raf
  • Receptor, Melanocortin, Type 1
  • Skin Neoplasms

abstract

  • To evaluate possible bone marrow toxic reaction related to allopurinol administration, 143 patients with malignant lymphoma were randomized to receive allopurinol for either three or six cycles of chemotherapy. There was no significant difference of nadir WBC or platelet counts. This trial failed to confirm an earlier study that suggested allopurinol increased the marrow toxic reaction of cytotoxic chemotherapy.

publication date

  • March 1982

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1001/jama.247.3.334

PubMed ID

  • 7033573

Additional Document Info

start page

  • 334

end page

  • 6

volume

  • 247

number

  • 3